Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 30Head & Neck 17Thoracic 14Genitourinary 9Gynecologic 7CNS 7Other hematologic neoplasm 6Lymphoid 5Sarcoma 4Other 2Breast 2Plasma cell 1NET 1Endocrine 1Dermatologic 1

Conditions

Multiple Myeloma 3082Neoplasms, Plasma Cell 614Lymphoma 455Lymphoma, Non-Hodgkin 428Recurrence 371Hodgkin Disease 366Leukemia, Lymphocytic, Chronic, B-Cell 362Precursor Cell Lymphoblastic Leukemia-Lymphoma 340Leukemia, Myeloid, Acute 322Leukemia 321Myelodysplastic Syndromes 287Lymphoma, Mantle-Cell 262Lymphoma, Large B-Cell, Diffuse 259Lymphoma, Follicular 254Lymphoma, B-Cell, Marginal Zone 231Burkitt Lymphoma 227Lymphoma, Large-Cell, Immunoblastic 203Myeloproliferative Disorders 197Immunoglobulin Light-chain Amyloidosis 184Neoplasms 182Hematologic Neoplasms 169Primary Myelofibrosis 167Leukemia, Myeloid, Chronic-Phase 165Leukemia, Myeloid, Accelerated Phase 154Lymphoma, T-Cell, Cutaneous 150Waldenstrom Macroglobulinemia 145Blast Crisis 143Leukemia, Myelomonocytic, Chronic 140Mycosis Fungoides 129Sezary Syndrome 128

Interventions

pomalidomide 1TH 302 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypoxia × Plasma cell × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡